401 - Pattern of bone metastasis and treatment outcomes of Chinese triple negative breast cancers

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Breast Cancer
Supportive and Palliative Care
Presenter Ying Fan
Authors Y. Fan1, X.Y. Ding2, F. Ma2, Q. Li2, J. Wang3, P. Yuan2, P. Zhang2, B. Xu3
  • 1Medical Oncology Dept., Cancer Hospital&Institute, Beijing/CN
  • 2Department Of Medical Oncology, Cancer Hospital&Institute, Beijing/CN
  • 3Medical Dept., Cancer Hospital&Institute, Beijing/CN



To investigate the characteristics of bone metastasis, prognosis and treatment strategies of triple negative breast cancer (TNBC) patients in China.


269 metastatic TNBC between Jan 1, 2005 and Dec 31, 2011 were retrospectively reviewed. Bone metastases were identified as primary metastatic site in 83 patients (30.8%). Among them, 25 patients (30.1%) had bone metastasis as the only relapse and the remaining were accompanied by involvement of other locations. Clinical pathologic characteristics and treatment outcomes were evaluated in these 83 cases.


Median age was 48.2 (22-84) years. Median disease-free survival was 30.3 month (95% CI: 8.9-58.9 months). In these patients with bone metastasis as the primary distant site, most of them had multiple osteolytic bone lesions (78.3%). The incidence of skeletal related events was 24.1%. Chemotherapy was administered as the first choice in majority of patients (75 out of 83, 90.4%). Overall response rate was 44.0%, including 1 CR (1.3%) and 32 PR (42.7%). Median time to progression (TTP) of first-line chemotherapy was 8.0 (95%CI 8.7-16.0) months and median overall survival (OS) was 30.0 (95%CI 30.8-47.4) months. No differences were seen when comparing taxanes-based with non-taxanes regimen, platinum-based with non-platinum regimen and capecitabine-contained with non-capecitabine regimen in terms of response rate, TTP and OS.


Although the incidence of bone metastasis in mTNBC were not as high as in Luminal type, it was also common in Chinese patients, different from previous literatures reported in western countries. The survival of metastatic TNBC with bone metastases is poor. Chemotherapy was without doubt the primary treatment options, however, no the superiority of any chemo-agent have been proved now.


All authors have declared no conflicts of interest.